INmune Bio
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 17
- Market Cap
- -
- Website
- http://www.inmunebio.com
- Introduction
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Study of INKmune in Patients With mCRPC (CaRe Prostate)
- Conditions
- Metastatic Castration-resistant Prostate CancerCancermCRPC
- Interventions
- First Posted Date
- 2023-09-28
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06056791
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States
A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML
- Conditions
- CancerMDS-EBAcute Myeloid LeukemiaMyelodysplastic SyndromesAML
- First Posted Date
- 2023-07-06
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05933070
- Locations
- 🇬🇷
Attikon University General Hospital, Athens, Attiki, Greece
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
🇬🇧Sheffield Teaching Hospitals NHS FT - Royal Hallamshire Hospital, Sheffield, United Kingdom
An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease
- Conditions
- Central Nervous System DiseasesTauopathiesMental DisordersAlzheimer DiseaseBrain DiseasesDementiaNeurodegenerative DiseasesNeurocognitive DisordersNervous System Diseases
- Interventions
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT05522387
- Locations
- 🇦🇺
KaRa MINDS, Macquarie Park, New South Wales, Australia
🇦🇺Neuro Trials Victoria Pty Ltd T/A NeuroCentrix, Carlton, Victoria, Australia
🇦🇺Austin Health, Ivanhoe, Victoria, Australia
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
- Conditions
- DementiaMild Cognitive Impairment (MCI)Alzheimer DiseaseBrain DiseasesNervous System DiseasesCentral Nervous System DiseasesTauopathiesNeurodegenerative DiseasesMental Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Inmune Bio, Inc.
- Registration Number
- NCT05321498
A Study of XPro1595 in Patients with Early Alzheimer's Disease with Biomarkers of Inflammation
- Conditions
- Alzheimer DiseaseDementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental DisordersMild Cognitive Impairment
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Inmune Bio, Inc.
- Target Recruit Count
- 201
- Registration Number
- NCT05318976
- Locations
- 🇬🇧
INmune Bio Investigational Site, Winchester, United Kingdom
- Prev
- 1
- 2
- Next